Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

October 25, 2024

Study Completion Date

October 31, 2025

Conditions
Acute Respiratory Distress SyndromeSepsis
Interventions
DRUG

Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)

Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.

OTHER

Inhaled Medical air

Inhaled Medical Air for up to 90 minutes daily for 3 days.

Trial Locations (6)

10065

Weill Cornell Medical College, New York

11215

New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn

27710

Duke University Hospital, Durham

63110

Washington University, St Louis

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Duke University

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Washington University School of Medicine

OTHER

lead

Brigham and Women's Hospital

OTHER

NCT04870125 - Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS) | Biotech Hunter | Biotech Hunter